Myocardial metabolic manipulation: A new therapeutic approach in heart failure?

Heart

Volumn 91, Issue 2, 2005, Pages 131-132

  O'Meara, E ^a   McMurray, John J V ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; TRIMETAZIDINE;

DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; FATTY ACIDS, NONESTERIFIED; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 12744271862     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.041756     Document Type: Editorial

References (10)

1. Jones RH. Is it time for a randomized trial of surgical treatment of ischemic heart failure? J Am Coll Cardiol 2001;37:1210-3.
2. Cleland JG, Freemantle N, Ball SG, et al. The heart failure revascularisation trial (HEART): rationale, design and methodology. Eur J Heart Fail 2003;5:295-303.
3. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004;25:634-41.
4. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8.
5. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91:161-5.
6. Rosano GM, Vitale C, Sposato B, et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003;2:16.
7. Thrainsdottir IS, von Bibra H, Malmberg K, et al. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 2004;44:101-8.
8. Sack MN, Rader TA, Park S, et al. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996;94:2837-42.
9. Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001;103:2441-6.
10. Chaitman BR, Pepine CJ, Parker JO, et al. for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 2004;291:309-16.